CAS NO: | 1800046-97-2 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally activeSYKinhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibitsSYKactivity in platelets via theglycoproteinVI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans[1][2][3]. | ||||||||||||||||
IC50& Target | IC50: 9.5 nM (SYK)[1] | ||||||||||||||||
体外研究 (In Vitro) | Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits anti-IgM stimulated phosphorylation of AKT, BLNK, BTK, ERK, MEK, and PKCδ in human B cells with EC50values of 24-51 nM. Lanraplenib monosuccinate inhibits anti-IgM mediated CD69 and CD86 expression on B-cells (EC50=112±10 nM and 164±15 nM, respectively) and anti-IgM /anti-CD40 co-stimulated B cell proliferation (EC50=108±55 nM). In human macrophages, Lanraplenib monosuccinate inhibits IC-stimulated TNFα and IL-1β release (EC50=121±77 nM and 9±17 nM, respectively)[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 561.59 | ||||||||||||||||
Formula | C27H31N9O5 | ||||||||||||||||
CAS 号 | 1800046-97-2 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 125 mg/mL(222.58 mM;Need ultrasonic) 配制储备液
In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|